To date, MRI is the reference neuroimaging modality used in MS assessment. Yet, due to its intrinsic disseminated essence, the processes linked to MS pathology have been difficult to visualize using conventional in-vivo imaging techniques, which are limited by low pathological specificity and low sensitivity to diffuse damage. Quantitative MRI techniques offer complementary information about the different components of brain tissue architecture. All of them have proven to be extremely sensitive to specific tissue abnormalities, albeit at the price of poor specificity. Combining the recent advances in qMRI using multimodal approaches may provide new biomarkers of disease severity and help to improve the clinical–radiological mismatch in MS treatment.